Cargando…
Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir
We hereby introduce a sensitive fast straightforward spectrofluorometric method for the estimation of remdesivir and favipiravir. The two drugs are prescribed in some regimens to treat COVID‐19 pandemic disease, which is caused by SARS‐CoV‐2. The method is based on the first derivative synchronous s...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244323/ https://www.ncbi.nlm.nih.gov/pubmed/35771341 http://dx.doi.org/10.1007/s10895-022-02998-z |
_version_ | 1784738499141828608 |
---|---|
author | El-Awady, Mohamed Elmansi, Heba Belal, Fathalla Shabana, Rasha abo |
author_facet | El-Awady, Mohamed Elmansi, Heba Belal, Fathalla Shabana, Rasha abo |
author_sort | El-Awady, Mohamed |
collection | PubMed |
description | We hereby introduce a sensitive fast straightforward spectrofluorometric method for the estimation of remdesivir and favipiravir. The two drugs are prescribed in some regimens to treat COVID‐19 pandemic disease, which is caused by SARS‐CoV‐2. The method is based on the first derivative synchronous spectrofluorimetry approach for the measurement of remdesivir and favipiravir. This was accomplished at 251 nm and 335 nm respectively using the first derivative order at delta lambda of 140 nm. A linear response with a correlation coefficient 0.9994 was achieved between the concentration and the derivative amplitudes in the ranges of 20.0–100.0 ng ml(−1) and 40.0–100.0 ng ml(−1) for remdesivir and favipiravir, respectively. The methods were validated for different parameters as stated by the pharmacopeial rules and were applied successfully for estimation of the studied drugs in their synthetic mixtures and in spiked human plasma samples. No significant difference was observed between the proposed and comparison methods as revealed from the analysis of data. |
format | Online Article Text |
id | pubmed-9244323 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-92443232022-06-30 Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir El-Awady, Mohamed Elmansi, Heba Belal, Fathalla Shabana, Rasha abo J Fluoresc Research We hereby introduce a sensitive fast straightforward spectrofluorometric method for the estimation of remdesivir and favipiravir. The two drugs are prescribed in some regimens to treat COVID‐19 pandemic disease, which is caused by SARS‐CoV‐2. The method is based on the first derivative synchronous spectrofluorimetry approach for the measurement of remdesivir and favipiravir. This was accomplished at 251 nm and 335 nm respectively using the first derivative order at delta lambda of 140 nm. A linear response with a correlation coefficient 0.9994 was achieved between the concentration and the derivative amplitudes in the ranges of 20.0–100.0 ng ml(−1) and 40.0–100.0 ng ml(−1) for remdesivir and favipiravir, respectively. The methods were validated for different parameters as stated by the pharmacopeial rules and were applied successfully for estimation of the studied drugs in their synthetic mixtures and in spiked human plasma samples. No significant difference was observed between the proposed and comparison methods as revealed from the analysis of data. Springer US 2022-06-30 2022 /pmc/articles/PMC9244323/ /pubmed/35771341 http://dx.doi.org/10.1007/s10895-022-02998-z Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research El-Awady, Mohamed Elmansi, Heba Belal, Fathalla Shabana, Rasha abo Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir |
title | Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir |
title_full | Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir |
title_fullStr | Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir |
title_full_unstemmed | Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir |
title_short | Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir |
title_sort | insights on the quantitative concurrent fluorescence-based analysis of anti-covid-19 drugs remdesivir and favipiravir |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244323/ https://www.ncbi.nlm.nih.gov/pubmed/35771341 http://dx.doi.org/10.1007/s10895-022-02998-z |
work_keys_str_mv | AT elawadymohamed insightsonthequantitativeconcurrentfluorescencebasedanalysisofanticovid19drugsremdesivirandfavipiravir AT elmansiheba insightsonthequantitativeconcurrentfluorescencebasedanalysisofanticovid19drugsremdesivirandfavipiravir AT belalfathalla insightsonthequantitativeconcurrentfluorescencebasedanalysisofanticovid19drugsremdesivirandfavipiravir AT shabanarashaabo insightsonthequantitativeconcurrentfluorescencebasedanalysisofanticovid19drugsremdesivirandfavipiravir |